CLOSE

The need to develop a coronavirus vaccine is increasing every day, but it will take time for the vaccine to reach the market.

USA TODAY

The U.S. announced on Friday it would pay French pharmaceutical company Sanofi and Britain’s GlaxoSmithKline up to $ 2.1 billion to test and produce 100 million doses of experimental coronavirus vaccines.

More than half of the money will go to further development and early-stage clinical trials to ensure they are safe and effective. The rest will be paid for the first 100 million doses, with a further 500 million doses selected.

The big $ 2.1 billion will go to Sanofi, which has announced a vaccine candidate. GlaxoSmithKline has made an enhancer that improves the body’s response to it.

The agreement is part of Operation Warp Speed, a White House-led initiative to get a vaccine to stop the SARS-CoV-2 virus, which causes COVID-19. Now, at the initiative of the Trump administration, more than $ 8 billion has been spent on experimental vaccines that can be produced across the finish line.

“Historical moment: Large-scale studies of potential COVID-19 vaccines are underway

Operation warp speed: Officials dismiss criticism, saying “We are taking all possible steps” to safely vaccinate COVID-19

Expert group: The early success of COVID-19 vaccine candidates encourages optimism, but experts warn that “a lot needs to be done right”

They are produced “at risk” – before licensing. If any vaccine is not approved, the stockpile will be destroyed.

The companies are working with the U.S. Department of Health and Human Services and the Department of Defense to increase their manufacturing capabilities in the U.S.

The Sanofi experimental vaccine uses DNA and has never been an experimental vaccine against the SARS virus. Phase 1 and 2 clinical trials of the vaccine candidate will begin in September, said Thomas Triomphe, global head of Sanofi Pasteur, Sanofi’s vaccine wing.

The potential vaccine could start Phase 3 trials, the final phase before licensing, by 2020. The end. If the vaccine proves to be safe and effective, they expect regulatory approval by 2021. In the first half.

This is the fourth deal in which the federal government has committed to buying doses if companies develop successful coronavirus vaccines.

CLOSE

Dr Anthony Fauci said on Tuesday that the development of a vaccine against coronavirus is moving fast. Fauci spoke when President Donald Trump announced on Tuesday a strong defense against the denied use of the malaria drug as a treatment.e coronavirus. (July 28)

AP internal

Under the agreement reached in May, the British and Swedish company AstraZeneca will receive $ 300 billion for 300 million doses. A $ 1.95 billion deal with U.S.-based Pfizer was announced in July for 100 million doses. Maryland-based Novavax announced in July that it would receive $ 1.6 billion from the government to develop its candidate vaccines, research and fund 100 million doses.

“The portfolio of vaccines that will be collected for Operation Warp Speed ​​increases the likelihood that we will have at least one safe and effective vaccine at the end of this year,” said Alex Azar, secretary of health and human services.

The latest agreement could “provide hundreds of millions of safe and effective doses to the American people,” he said.

Sanofi and GSK have said they are committed to distributing the vaccine worldwide and are building production capacity to produce up to 1 billion doses a year.

The candidate for DNA-based vaccines is one of two companies that work. The other is the RNN vaccine, the same type of Moderna.

In the second study, they plan to launch Phase 1 trials by 2020. The vaccine is nearing completion and plans to begin approval in 2021. In the second half, the company reported.

Read or share this story: https://www.usatoday.com/story/news/2020/07/31/2-1-billion-sanofi-gsk-deal-100-million-coronavirus-vaccine-doses/5554814002/